Artemether and the Pharma Industry: A Strategic Asset

 Malaria as the Burden- Heavy in Tropical Nations Malaria has been one of the biggest Public Health challenges faced across the globe, making inroads into the lives of millions residing in tropical and subtropical areas. Active Pharmaceutical Ingredients are the backbone of any disease prevention and cure methodology around the world, when it comes to the war against infectious diseases carried by vector control. Among the pool of crucial bulk active substances, one key ingredient comes to notice- Artemether API.

Artemether, an important lipid-soluble and power packed derivative of artemisinin, has been a game changing drug that has redefined tropical medicine and treatment for malaria.

For many pharmaceutical firms, procurement agents, and formulation development experts, it is absolutely vital to assure consistent access to high standard malaria therapeutic APIs. Since the requirement and the purchasing quantity of these antimalarial bulk drugs have been soaring significantly around malaria infested nations, it is vital to appreciate its role.

The Therapeutic Significance of Artemether 

Artemether, or arteether as it's sometimes called, is a semi-synthetic form of the methylated and reduced active principle of the plant Artemisia annua. Unlike most anti-malarials, Artemether has shown effectiveness in combating drug-resistant forms of Plasmodium falciparum, which can cause the most deadly varieties of malaria. 

Rapid Clearance of Parasitemia 

A key differentiator compared to other older antimalarial drugs is that the mechanism by which Artemether works to kill the parasite takes place so rapidly. Soon after taking Artemether orally, an iron element in contact with the endoperoxide bond in the Artemether breaks the chemical bonds forming reactive oxygen free radicals (ROS) which effectively destroy damaging parasitic red blood cell membrane and vital cellular protein. This is why patients experience quick and effective relief of their symptoms.

The Power of Artemisinin-based Combination Therapies (ACTs) 

To avoid the development of drug resistance the WHO highly recommends for the use of Artemisinin-based Combination Therapies (ACTs) as the first-line treatment of uncomplicated P. Falciparum malaria. The ACT combination most notably Artemether-Lumefantrine provides an unsurpassed approach. In these fixed-dose combinations, the fast acting drug Artemether eliminates the malaria parasites quickly in the early hours after treatment is commenced whereas Lumefantrine-a longer lasting combination partner, eliminating any remaining parasites over the following few days thus preventing recrudescence.

Why Artemether is a Strategic Asset for Pharma Formulators 

The strategic importance of Artemether To the formulator and the manufacturer alike, Artemether is more than another active pharmaceutical ingredient, it is essential for significant and ongoing revenue streams and a strategically critical factor for those serving the international pharmaceutical industry.

High Demand Across Endemic Markets 

Due to the on-going health risks associated with malaria in Africa (Sub-Saharan Africa), the Far East (SE Asia), and parts of the Latin Americas, a non-fluctuating and consistent supply requirement exists for Artemether. The routine procurement of bulk quantities of ACT FDF by national health authorities, international NGOs and private hospitals/clinics means thatUSP/EP grade Artemether forms a stable component of a contemporary drug substance sourcing portfolio.

Formulation Versatility 

The unique physicochemical properties of Artemether provide formulation chemists with numerous options for designing finished dosage forms: • Oral solid dosages include immediate-release dosage form and tablet fixed dosage form when combined with Lumefantrine • Pediatric formulation: The dry syrup, which can be dispersible in the table-ted form, was used to create formulations suitable for infants and children, and thereby, enhance patient compliances. • Injectable intramuscular: A solution form prepared from the clarified vegeteble oil provide life saving parenteral formulation to the severe cerebral malaria, whose unable to the taken oral medic.

Manufacturing Standards & Quality Assurance in API Synthesis 

Producing top quality Artemether needs a strong background in sophisticated organic synthesis, fine control of the crystallisation and adherence to the principles of cGMP. As Artemether is used by very susceptible patient groups extremely high levels of purity are critical.

Critical Quality Attributes (CQAs) 

A reputable Artemether manufacturer will strive to ensure the manufacturing process stays within specification for the following. 1 . Chemical purity and impurity profile: This will limit related substances, also synthesis byproducts – including a proper limit for residual alpha/beta anomer ratio - to ensure safety and drug efficacy.

2. Residual Solvent Levels: Tight GC specification for the organic solvents used throughout synthesis and Crystallisation - this can be ensured well within ICH limits.

3. Polymorph Consistency: Ensuring no batch-to-batch variation in crystal modification and particle size – thus maintaining a predictable bioavailability, dissolution rate and tabletting compressibility. 4. Thermal and Storage Stability: The Bulk API should remain stable across its full range of exposure – in particular for our Zone IV (hot & humid) climatic stability condition.

The Strategic Advantage of API Manufacturing in India with Prism Industries Pvt. Ltd. 

The pharma hub of the world as India has been called, with India solutions API production globally highest of a low cost and qualitative products, there can’t be anything better than partner-ship of Prism Industries Pvt. Ltd., for your companies seeking reliable source of APIs in bulk as well.

Uncompromising Quality and Compliance 

Every batch we produce, at Prism Industries Pvt. Ltd. Begins with rigorous Quality Assurance. We operate world class manufacturing facilities which adhere to various global quality management standards, delivering our Artemether API and associated antimalarial active ingredients to conform to prevailing USP, EP, IP Pharmacopeial.

Securing the B2B Pharma Supply Chain 

International global supply chain disruptions indicate the need to team with consistent API providers. Prism Industries Pvt. Ltd has built a formidable B2B pharma supply chain infrastructure with… .

Enhanced Process Control, Robust Technical Data, Batch–to–Batch Reproducibility.

“ PrISM’s global reach and a seamless delivery process ensures we consistently receive High – Quality … The World’s first of 16 Novel drug Molecules is developed through us.” “It is difficult for the global pharmaceutical organizations to meet the ever evolving demand of medicines world over in time. Hence,” It’s always best to have a steady, reliable manufacturing partner for APIs, who possess …

Conclusion 

An irreplaceable column in today's global combat against malaria, the rapid acting therapeutic effect, the combination as part of WH0 guidelines in ACT treatments, and various formulation options makes Artemether an important part of the product portfolio for pharmaceutical producers around the world. Working with a leading Artemether supplier for bulk active ingredients, such as Prism Industries Pvt. Ltd.

Becomes more and more important due to increased regulation and a growing demand in effective anti-malarial remedies.

Prism delivers API and all other necessary support like regulatory, supply chain aso for a global go to market strategy. To request our highest grade Artemether API, the respective specification, bulk, and other commercial topics please get in touch with our sales representatives.